Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Fig. 3

Human PD1-Fc-OX40L ARC binds efficiently to cells expressing PD-L1, PD-L2, and OX40 in vitro and ex vivo. The in vitro cell binding affinity of the human PD1-Fc-OX40L ARC was assessed using stable cell lines engineered to express high-levels of human PD-L1 (CHOK1/hPD-L1), human PD-L2 (CHOK1/hPD-L2), and human OX40 (Jurkat/hOX40 and HeLa/hOX40). a Representative immunofluorescence and (b) flow cytometry binding analysis to PD-L1, (top) PD-L2 and (middle) OX40 (bottom) expressing cells, generating dose-response plots to derive EC50 values

Back to article page